NCT01894165 - Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Molybdenum Cofactor Deficiency (MoCD)Rare Autosomal Recessive DisorderDeficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

Interventions

DRUG

ALXN1101

Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.

DRUG

Placebo

Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.

Trial Locations (1)

21225

Parexel Baltimore EPCU, Baltimore